All terms
Clinical & TrialsClinical Evidence
Primary and Secondary Endpoints
The pre-specified outcomes that determine trial success (primary), provide supporting evidence (secondary), or generate hypotheses (exploratory).
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026
Definition
The primary endpoint is the pre-specified outcome on which the trial is statistically powered and on which trial success or failure is judged. Secondary endpoints provide supporting evidence — additional efficacy claims, safety, or quality-of-life — and are typically tested under a pre-specified hierarchical or alpha-allocation procedure to control multiplicity. Exploratory endpoints generate hypotheses for future studies and do not support label or coverage claims. Endpoint choice and ordering is the single most consequential design decision in a pivotal trial. What the regulation says
ICH E9 'Statistical Principles for Clinical Trials' and ICH E9(R1) addendum on Estimands govern endpoint specification. FDA's 'Multiple Endpoints in Clinical Trials' guidance (2022) details multiplicity control.
What this means in practice
MedTech sponsors increasingly use composite primary endpoints (MACE in cardiovascular, KCCQ in heart failure) and pre-specify hierarchical secondary testing to maximize labelable claims. Common pitfalls
- •Adding endpoints during trial conduct — almost always destroys their interpretability.
- •Failing to control multiplicity across secondary endpoints, leaving label claims unsupported.
Primary references
3 sourcesLink health: 2 verified 1 bot-blocked· last checked 2026-05-09
FDA·1ICH·2
- 1
FDA — Multiple Endpoints in Clinical Trials (2022)Bot-blockedFDAfda.gov
- 2
ICH E9(R1) EstimandsVerifiedICHich.org
- 3
ICH GuidelinesVerifiedICHich.org
Inline markers like [1] jump to the matching reference above.